<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03628677</url>
  </required_header>
  <id_info>
    <org_study_id>AB154CSP0001</org_study_id>
    <nct_id>NCT03628677</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety,&#xD;
      tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in&#xD;
      combination with zimberelimab (AB122) in participants with advanced solid malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety,&#xD;
      tolerability, PK, PD, and clinical activity of domvanalimab as monotherapy and in combination&#xD;
      with zimberelimab in participants with advanced solid malignancies. In this dose escalation&#xD;
      study, participants will receive domvanalimab administered intravenously as monotherapy or in&#xD;
      combination with zimberelimab. Treatment will continue until progressive disease,&#xD;
      unacceptable toxicity, withdrawal of consent, or other reasons for study drug discontinuation&#xD;
      occurs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Anticipated">May 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose Escalation Design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0</measure>
    <time_frame>From First Dose Date to 90 Days After Last Dose</time_frame>
    <description>Number of Participants Treated with domvanalimab or domvanalimab in Combination with zimberelimab with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AB154 Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Peak Plasma Concentration (Cmax) of domvanalimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zimberelimab Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Peak Plasma Concentration (Cmax) of zimberelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Domvanalimab Time of Peak Concentration (Tmax)</measure>
    <time_frame>Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Time of Peak Concentration (Tmax) of domvanalimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zimberelimab Time of Peak Concentration (Tmax)</measure>
    <time_frame>Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Time of Peak Concentration (Tmax) of zimberelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Domvanalimab Area Under the Plasma Concentration Versus Time Curve (AUC)</measure>
    <time_frame>Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Area Under the Plasma Concentration Versus Time Curve (AUC) of domvanalimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zimberelimab Area Under the Plasma Concentration Versus Time Curve (AUC)</measure>
    <time_frame>Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Area Under the Plasma Concentration Versus Time Curve (AUC) of zimberelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Indicators: Anti-Drug Antibodies (ADA)</measure>
    <time_frame>Day 1, Day 15, Day 29, Day 43, Day 57, Day 85 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Number of Participants who Develop Antidrug Antibodies to AB154 and/or AB122</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>First Dose Date to Progression or Last Tumor Assessment, up to 1 year</time_frame>
    <description>Number of Participants with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Start Date of Response to First Progression/Death, up to 1 year</time_frame>
    <description>Time at Which Response Criteria are Met for Complete Response or Partial Response (Whichever Occurs First) Until the First Date of Recurrence, Progression or Death per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>First Dose Date to First Progression/Death, up to 1 year</time_frame>
    <description>Number of Participants with Complete Response, Partial Response, or Stable Disease for Greater Than 6 Months per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>First Dose Date to First Progression/Death, up to 1 year</time_frame>
    <description>Number of Participants Without Disease Progression per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>First Dose Date to Date of Death, up to 1 year</time_frame>
    <description>Overall Survival Rate, Defined as Time Between First Dose Date and Date of Death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Domvanalimab Receptor Occupancy</measure>
    <time_frame>Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Receptor Occupancy May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Domvanalimab Immunophenotyping</measure>
    <time_frame>Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Immunophenotyping May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Domvanalimab Gene Expression</measure>
    <time_frame>Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Gene Expression May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Domvanalimab Cytokines</measure>
    <time_frame>Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Cytokines May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>.Zimberelimab Receptor Occupancy</measure>
    <time_frame>Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Receptor Occupancy May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Zimberelimab Immunophenotyping</measure>
    <time_frame>Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Immunophenotyping May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Zimberelimab Cytokines</measure>
    <time_frame>: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Cytokines May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Zimberelimab Gene Expression</measure>
    <time_frame>Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141, and 30 Days After Last Dose, up to 52 weeks</time_frame>
    <description>Gene Expression May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Solid Tumor, Unspecified, Adult</condition>
  <arm_group>
    <arm_group_label>Domvanalimab Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying Doses of domvanalimab Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Domvanalimab + zimberelimab Q2W Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Domvanalimab + zimberelimab Q3W Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Domvanalimab + zimberelimab Q4W Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Domvanalimab and Zimberelimab Q6W combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domvanalimab</intervention_name>
    <description>Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT</description>
    <arm_group_label>Domvanalimab + zimberelimab Q2W Combination Therapy</arm_group_label>
    <arm_group_label>Domvanalimab + zimberelimab Q3W Combination Therapy</arm_group_label>
    <arm_group_label>Domvanalimab + zimberelimab Q4W Combination Therapy</arm_group_label>
    <arm_group_label>Domvanalimab Monotherapy</arm_group_label>
    <arm_group_label>Domvanalimab and Zimberelimab Q6W combination therapy</arm_group_label>
    <arm_group_label>Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W</arm_group_label>
    <other_name>AB154</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zimberelimab</intervention_name>
    <description>Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1</description>
    <arm_group_label>Domvanalimab + zimberelimab Q2W Combination Therapy</arm_group_label>
    <arm_group_label>Domvanalimab + zimberelimab Q3W Combination Therapy</arm_group_label>
    <arm_group_label>Domvanalimab + zimberelimab Q4W Combination Therapy</arm_group_label>
    <arm_group_label>Domvanalimab and Zimberelimab Q6W combination therapy</arm_group_label>
    <arm_group_label>Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W</arm_group_label>
    <other_name>AB122</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of giving signed informed consent&#xD;
&#xD;
          2. Male or female participants ≥ 18 years of age at the time of screening&#xD;
&#xD;
          3. Negative serum pregnancy test at screening and prior to dosing on Cycle 1 Day 1;&#xD;
             negative serum or urine pregnancy test on the first day of each subsequent treatment&#xD;
             period&#xD;
&#xD;
          4. Participants with any pathologically confirmed solid tumor type for which no standard&#xD;
             of care therapy exists&#xD;
&#xD;
          5. Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1. The measurable lesion must be outside of a radiation field if&#xD;
             the participant received prior radiation&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1&#xD;
&#xD;
          7. Confirmation that an archival tissue sample is available and ≤ 6 months old; if not, a&#xD;
             new biopsy of a tumor must be obtained&#xD;
&#xD;
          8. Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed&#xD;
             topical corticosteroids (doses &gt; 10 mg/day prednisone or equivalent) must be&#xD;
             discontinued at least 2 weeks (14 days) before investigational product administration.&#xD;
             Physiologic doses of corticosteroids ≤ 10 mg/day of prednisone or its equivalent may&#xD;
             be permitted&#xD;
&#xD;
          9. Prior surgery that required general anesthesia or other major surgery as defined by&#xD;
             the Investigator must be completed at least 4 weeks before investigational product&#xD;
             administration&#xD;
&#xD;
         10. Negative tests for hepatitis B surface antigen, hepatitis C virus antibody (or&#xD;
             hepatitis C qualitative ribonucleic acid [RNA; qualitative]), and human&#xD;
             immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening&#xD;
&#xD;
        12. Adequate organ and marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any live vaccines against infectious diseases (eg, influenza, varicella) within&#xD;
             4 weeks (28 days) of initiation of investigational product&#xD;
&#xD;
          2. Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will&#xD;
             make the administration of investigational product hazardous (eg, interstitial lung&#xD;
             disease, active infections requiring antibiotics, recent hospitalization with&#xD;
             unresolved symptoms)&#xD;
&#xD;
          3. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial&#xD;
&#xD;
          4. Is pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the pre-screening or screening visit&#xD;
             through 100 days after the last dose of domvanalimab as monotherapy and in combination&#xD;
             with zimberelimab.&#xD;
&#xD;
          5. Participants who require a Legally Authorized Representative (LAR) to provide informed&#xD;
             consent on their behalf.&#xD;
&#xD;
          6. Any active autoimmune disease or a documented history of autoimmune disease or history&#xD;
             of a syndrome that required systemic steroids or immunosuppressive medications, except&#xD;
             for vitiligo or resolved childhood asthma/atopy. Participants with asthma who require&#xD;
             intermittent use of bronchodilators (such as albuterol) will not be excluded from this&#xD;
             study&#xD;
&#xD;
          7. Prior malignancy active within the previous year except for locally curable cancers&#xD;
             that have been apparently cured, such as basal or squamous cell skin cancer,&#xD;
             superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate&#xD;
             cancer&#xD;
&#xD;
          8. Has had prior chemotherapy, targeted small-molecule therapy, immunotherapy (tumor&#xD;
             vaccine, cytokine, or growth factor given to control the cancer), biologic agents or&#xD;
             radiation therapy within 4 weeks (or 5 half-lives) prior to Day 1 or has not recovered&#xD;
             from AEs due to a previously administered agent&#xD;
&#xD;
          9. Use of other investigational drugs within 28 days or at least 5 half-lives before&#xD;
             investigational product administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Arcus Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>510-694-6220</phone>
    <email>clinicaltrials@arcusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Azada</last_name>
      <phone>310-231-2182</phone>
      <email>mazada@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Ani Balmanoukian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley McClain</last_name>
      <phone>980-441-1021</phone>
      <email>amcclain@carolinabiooncology.org</email>
    </contact>
    <investigator>
      <last_name>John Powderly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>START</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Eckhart</last_name>
      <phone>210-593-2574</phone>
      <email>Carrie.Eckart@startsa.com</email>
    </contact>
    <investigator>
      <last_name>Amita Patnaik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS (dba Summit Cancer Centers)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Chaudhry</last_name>
      <phone>509-462-2273</phone>
      <email>chaudhrym@nwrm.com</email>
    </contact>
    <investigator>
      <last_name>Arvind Chaudhry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albury, Australia</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Principal Investigator</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Kinghorn Cancer Centre</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kent</last_name>
      <email>robert.kent@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Amy Prawira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scientia Clinical Research</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Sim</last_name>
      <email>justin.sim@scientiaclinicalresearch.com.au</email>
    </contact>
    <investigator>
      <last_name>James Kuo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Principal Investigator</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Principal Investigator</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Olivia Newton-John Cancer Research Institute</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Arcus will provide access to individual de-identified participant data and related study documents [e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)] upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

